Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1B Cash, $31.50/Share

What happened

The boards of both companies have unanimously approved the acquisition of Catalyst by Angelini Pharma for $31.50 per share in cash, valuing the company at approximately $4.1 billion. This represents a 28% premium to the 30-day VWAP but is significantly below the ~$108 per share DCF intrinsic value estimated in the DeepValue analysis. The deal provides Angelini with immediate entry into the U.S. market and bolsters its brain health and rare disease portfolio. Catalyst shareholders will forgo potential long-term upside from FIRDAPSE patent protection, AGAMREE growth, and international expansion in exchange for a fixed cash price. Closing is expected in the third quarter of 2026, subject to regulatory and shareholder approvals.

Implication

For investors, the acquisition locks in a 28% premium to recent trading but leaves significant value on the table relative to the DCF-derived intrinsic value of $108 per share. Those who bought shares at or above $31.50 may realize a loss; those who accumulated at lower prices capture the premium. The deal removes execution risk tied to FYCOMPA generics, ANDA litigation, and AGAMREE adoption, but sacrifices potential multi-year compounding. Shareholders should assess whether the price adequately compensates for the long-term value of Catalyst’s rare-disease assets and patent protection. The likelihood of a higher bid is low given the unanimous board approval and strategic fit for Angelini.

Thesis delta

The buy thesis is effectively moot as the cash offer ends the standalone valuation story. While the DeepValue report saw significant upside to $108, the acquisition at $31.50 delivers a modest premium but far below that target. Investors should shift from evaluating operational execution to assessing the fairness of the offer and potential for competing bids.